Figure 1

Asarinin improved lung tissue morphology and structure and reduced lung fibrosis marker levels. A mouse lung fibrosis model was constructed using BLM, and high (20 mg/kg), medium (5 mg/kg), and low (1 mg/kg) doses of asarinin were injected intraperitoneally to assess the direct antifibrotic effect of asarinin (A). Hematoxylin and eosin staining and Masson staining analysis for changes in lung tissue structure and extracellular matrix deposition (magnification ×100) (B,C). Ashcroft score analysis for the degree of pulmonary fibrosis (H). Record the number of deaths in each group of mice and make a survival curve (F). Immunohistochemical analysis for the expression of α-SMA and type I collagen in lung tissue (magnification ×100) (D,E). Biochemical methods were used to determine the hydroxyproline content of lung tissue (G). Quantitative real-time PCR analysis for the gene expression levels of Acta2 with Col1a1 in lung tissue (I,J). Western blot analysis of α-SMA and type I collagen protein levels in lung tissue (K,L). Control represents the control group; BLM represents the pulmonary fibrosis model group; BLM+L represents the low-dose asarinin treatment group; BLM +M represents the medium-dose asarinin treatment group; BLM + H represents the high-dose asarinin treatment group. Data are expressed as mean ± standard deviation, sample size (n) = 8 for each group, *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.